Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Energy Select Sector SPDR Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B), while Energy Select Sector SPDR Fund trades at $60.78. Which is the better fit depends on your goals.
| VRTX | XLE | |
|---|---|---|
Market Cap | $132.79B | — |
Sector | Health | — |
52-Week High | $529.65 | $62.57 |
52-Week Low | $376.62 | $42.33 |
Enterprise Value | $126.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
XLE (Energy Select Sector SPDR ETF) trades at $57.48, down 1.17% amid bearish technical signals. The ETF faces headwinds despite strong energy sector performance driven by geopolitical tensions and elevated oil prices. Recent earnings from major holdings like ExxonMobil and Chevron showed profit surges, but technical indicators suggest near-term weakness with resistance at $58 and support at $57.
Outlook remains mixed with geopolitical risks supporting oil prices but technical weakness suggesting caution. The concentrated exposure to major energy companies provides stability but limits diversification. Key risks include oil price volatility and Middle East tensions, while the low expense ratio of 0.08% maintains cost efficiency for long-term energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
